Yubin Ge

List of Publications by Year
in descending order

128	4,921	76196 40	114278 63
papers	citations	h-index	g-index

128	128	128	6624
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine, 2022, 26, 2646-2657.	1.6	9
2	The paradox of Myeloid Leukemia associated with Down syndrome. Biochemical Pharmacology, 2022, 201, 115046.	2.0	6
3	â€œFLippingâ€•the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. Cancers, 2022, 14, 3398.	1.7	9
4	The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica, 2021, 106, 1262-1277.	1.7	24
5	Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. Blood, 2021, 137, 3641-3655.	0.6	20
6	The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer Journal, 2021, 11, 111.	2.8	22
7	When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3â€ITD AML. Pediatric Blood and Cancer, 2021, 68, e29278.	0.8	2
8	MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition. EBioMedicine, 2021, 70, 103488.	2.7	0
9	Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. Biochemical Pharmacology, 2020, 182, 114253.	2.0	29
10	A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia. Scientific Reports, 2020, 10, 18514.	1.6	5
11	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	2.0	12
12	Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers, 2020, 12, 2400.	1.7	26
13	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy, 2020, 5, 288.	7.1	98
14	A userâ€™s guide to lorlatinib. Critical Reviews in Oncology/Hematology, 2020, 151, 102969.	2.0	26
15	COVIDâ€19 and childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28400.	0.8	17
16	CUDCâ€907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. Journal of Cellular and Molecular Medicine, 2020, 24, 7239-7253.	1.6	35
17	Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2020, 5, 17.	7.1	43
18	Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment. Blood, 2020, 136, 20-20.	0.6	0

#	Article	IF	Citations
19	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 6815-6826.	3.2	115
20	Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leukemia Research, 2019, 84, 106180.	0.4	41
21	Monozygotic twins with neuroblastoma MS have a similar molecular profile: a case of twin-to-twin metastasis. British Journal of Cancer, 2019, 121, 890-893.	2.9	4
22	A delicate balance â€“ The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochemical Pharmacology, 2019, 162, 250-261.	2.0	135
23	Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia . Cancer Management and Research, 2019, Volume 11, 3197-3213.	0.9	16
24	Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. Targeted Oncology, 2019, 14, 351-364.	1.7	5
25	Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Haematologica, 2019, 104, 2225-2240.	1.7	53
26	Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2019, 4, 44.	7.1	4
27	ONC201 shows promise in AML treatment. Cell Cycle, 2018, 17, 277-277.	1.3	7
28	Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochemical Pharmacology, 2018, 148, 13-26.	2.0	38
29	A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. Cancer Cell, 2018, 34, 707-723.e7.	7.7	68
30	Inhibition of <scp>XPO</scp>1 enhances cell death induced by <scp>ABT</scp>â€199 in acute myeloid leukaemia via Mclâ€1. Journal of Cellular and Molecular Medicine, 2018, 22, 6099-6111.	1.6	42
31	H₂O₂/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells. ACS Medicinal Chemistry Letters, 2018, 9, 635-640.	1.3	42
32	Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia. Blood, 2018, 132, 1361-1361.	0.6	2
33	Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia. Blood, 2018, 132, 3936-3936.	0.6	0
34	Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Scientific Reports, 2017, 7, 41950.	1.6	42
35	Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy, 2017, 2, 17012.	7.1	104
36	Improved outcomes for myeloid leukemia of Down syndrome: a report from the Childrenâ€™s Oncology Group AAML0431 trial. Blood, 2017, 129, 3304-3313.	0.6	71

#	Article	IF	Citations
37	An unexpected protein interaction promotes drug resistance in leukemia. Nature Communications, 2017, 8, 1547.	5.8	19
38	Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases. Journal of Pediatric Hematology/Oncology, 2017, 39, e332-e335.	0.3	12
39	Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. Oncology Reports, 2017, 37, 3377-3386.	1.2	22
40	Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Oncotarget, 2017, 8, 6319-6329.	0.8	26
41	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget, 2017, 8, 44295-44311.	0.8	29
42	Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Oncotarget, 2016, 7, 34785-34799.	0.8	35
43	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clinical Cancer Research, 2016, 22, 4440-4451.	3.2	176
44	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells. Journal of Medicinal Chemistry, 2016, 59, 7974-7990.	2.9	33
45	Etiology of Leukemia in Children with Down Syndrome. , 2016, , 89-108.		0
46	Gene Signature of High White Blood Cell Count in B-Precursor Acute Lymphoblastic Leukemia. PLoS ONE, 2016, 11, e0161539.	1.1	8
47	Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget, 2016, 7, 57171-57185.	0.8	21
48	Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo. Blood, 2016, 128, 1571-1571.	0.6	0
49	Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia. American Journal of Translational Research (discontinued), 2016, 8, 3893-3902.	0.0	13
50	MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Blood, 2015, 125, 1292-1301.	0.6	66
51	Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Molecular Oncology, 2015, 9, 409-421.	2.1	35
52	Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biology and Therapy, 2015, 16, 1784-1793.	1.5	32
53	Natural plant flavonoid apigenin directly disrupts Hsp90/Cdc37 complex and inhibits pancreatic cancer cell growth and migration. Journal of Functional Foods, 2015, 18, 10-21.	1.6	28
54	Targeting histone deacetylases (HDACs) and Wee1 for treating highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 52-59.	0.8	8

#	Article	IF	Citations
55	Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Letters, 2015, 356, 656-668.	3.2	32
56	Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells. Blood, 2015, 126, 1265-1265.	0.6	2
57	Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells. Blood, 2015, 126, 2469-2469.	0.6	1
58	Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatric Blood and Cancer, 2014, 61, 1767-1773.	0.8	28
59	Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia, 2014, 28, 1557-1560.	3.3	87
60	Knockdown of endogenous myostatin promotes sheep myoblast proliferation. In Vitro Cellular and Developmental Biology - Animal, 2014, 50, 94-102.	0.7	12
61	Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Review of Hematology, 2014, 7, 831-840.	1.0	24
62	CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. Journal of Hematology and Oncology, 2014, 7, 53.	6.9	41
63	Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Letters, 2014, 348, 20-28.	3.2	24
64	Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells. Oncology Reports, 2014, 32, 2789-2794.	1.2	10
65	Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Research, 2013, 107, 231-237.	0.8	27
66	Expression and purification of recombinant NRL-Hsp90Î± and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening. Protein Expression and Purification, 2013, 92, 119-127.	0.6	2
67	The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells. Archives of Biochemistry and Biophysics, 2013, 535, 120-127.	1.4	16
68	Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2013, 434, 95-101.	1.0	67
69	Overexpression of GATA1 Confers Resistance to Chemotherapy in Acute Megakaryocytic Leukemia. PLoS ONE, 2013, 8, e68601.	1.1	17
70	Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells. PLoS ONE, 2013, 8, e76662.	1.1	32
71	Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. PLoS ONE, 2013, 8, e79106.	1.1	76
72	Targeting The Wee1 Kinase With MK-1775 For Treatment Of Acute Myeloid Leukemia In The Down Syndrome Population. Blood, 2013, 122, 3836-3836.	0.6	0

#	Article	IF	Citations
73	The critical role of myostatin in differentiation of sheep myoblasts. Biochemical and Biophysical Research Communications, 2012, 422, 381-386.	1.0	18
74	Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood and Cancer, 2012, 59, 1245-1251.	0.8	21
75	Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. PLoS ONE, 2012, 7, e52095.	1.1	41
76	Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy and Behavior, 2011, 21, 27-30.	0.9	53
77	Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines. Molecular Medicine Reports, 2011, 5, 734-8.	1.1	5
78	Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. Journal of Cellular Physiology, 2011, 226, 2316-2328.	2.0	145
79	Acute Megakaryoblastic Leukemia Without <i>GATA1</i> Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. Journal of Clinical Oncology, 2011, 29, e230-e233.	0.8	15
80	Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells. PLoS ONE, 2011, 6, e17138.	1.1	47
81	A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy. PLoS ONE, 2011, 6, e27486.	1.1	11
82	Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. International Journal of Molecular Medicine, 2010, 25, 465-70.	1.8	32
83	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5499-5510.	3.2	71
84	Unique clinical and biological features of leukemia in Down syndrome children. Expert Review of Hematology, 2010, 3, 175-186.	1.0	17
85	Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment. Molecular Cancer Therapeutics, 2010, 9, 2016-2025.	1.9	32
86	Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy. , 2010, , 109-122.		0
87	The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia, 2009, 23, 1417-1425.	3.3	132
88	Down Syndrome and Malignancies: A Unique Clinical Relationship. Journal of Molecular Diagnostics, 2009, 11, 371-380.	1.2	86
89	RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood, 2009, 114, 2744-2752.	0.6	81
90	Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood, 2009, 114, 2753-2763.	0.6	65

#	Article	IF	Citations
91	Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia, 2008, 22, 1692-1697.	3.3	67
92	Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group. Oncogene, 2008, 27, 4933-4942.	2.6	18
93	The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia, 2008, 22, 521-529.	3.3	46
94	Down syndrome and leukemia: A model of leukemogenesis and cure. International Journal on Disability and Human Development, 2008, 7, .	0.2	0
95	Prognostic Role of the Reduced Folate Carrier, the Major Membrane Transporter for Methotrexate, in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2007, 13, 451-457.	3.2	23
96	Association between prenatal pesticide exposures and the generation of leukemia-associated T(8;21). Pediatric Blood and Cancer, 2007, 49, 624-628.	0.8	57
97	Effects of 5â€² untranslated region diversity on the posttranscriptional regulation of the human reduced folate carrier. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2007, 1769, 131-138.	2.4	22
98	Transcription factor GATA-1 and Down syndrome leukemogenesis. Leukemia and Lymphoma, 2006, 47, 986-997.	0.6	25
99	Risk for leukemia in infants without down syndrome who have transient myeloproliferative disorder. Journal of Pediatrics, 2006, 148, 687-689.	0.9	32
100	Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood, 2006, 107, 1570-1581.	0.6	99
101	The GATA site-dependent hemogen promoter is transcriptionally regulated by GATA1 in hematopoietic and leukemia cells. Leukemia, 2006, 20, 417-425.	3.3	23
102	Age-Related Loss of the DNA Repair Response Following Exposure to Oxidative Stress. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 427-434.	1.7	44
103	Transcriptional Regulation of the Human Reduced Folate Carrier in Childhood Acute Lymphoblastic Leukemia Cells. Clinical Cancer Research, 2006, 12, 608-616.	3.2	19
104	Role of USF1 in the differential expression of the human deoxycytidine kinase gene in acute myeloid leukemia. Leukemia, 2005, 19, 677-679.	3.3	4
105	Transcriptional regulation of the human reduced folate carrier promoter C: synergistic transactivation by Sp1 and C/EBP Î² and identification of a downstream repressor. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1727, 45-57.	2.4	17
106	Transcriptional regulation of the human reduced folate carrier A1/A2 promoter: Identification of critical roles for the USF and GATA families of transcription factors. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1731, 115-124.	2.4	11
107	Down syndrome, drug metabolism and chromosome 21. Pediatric Blood and Cancer, 2005, 44, 33-39.	0.8	99
108	Structure and Regulation of the Murine Reduced Folate Carrier Gene. Journal of Biological Chemistry, 2005, 280, 5588-5597.	1.6	49

#	Article	IF	Citations
109	GATA1, Cytidine Deaminase, and the High Cure Rate of Down Syndrome Children With Acute Megakaryocytic Leukemia. Journal of the National Cancer Institute, 2005, 97, 226-231.	3.0	107
110	The Prenatal Origin of Childhood Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2004, 45, 19-25.	0.6	37
111	The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines. Cancer Research, 2004, 64, 728-735.	0.4	78
112	Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood, 2004, 104, 1588-1589.	0.6	95
113	Roles of USF, Ikaros and Sp proteins in the transcriptional regulation of the human reduced folate carrier B promoter. Biochemical Journal, 2004, 383, 249-257.	1.7	30
114	Physical and Functional Interactions between USF and Sp1 Proteins Regulate Human Deoxycytidine Kinase Promoter Activity. Journal of Biological Chemistry, 2003, 278, 49901-49910.	1.6	42
115	The Phosphatase MKP1 Is a Transcriptional Target of p53 Involved in Cell Cycle Regulation. Journal of Biological Chemistry, 2003, 278, 41059-41068.	1.6	92
116	Transcriptional regulation of the cystathionine-Î²-synthase gene in Down syndrome and nonâ€"Down syndrome megakaryocytic leukemia cell lines. Blood, 2003, 101, 1551-1557.	0.6	46
117	High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood, 2002, 99, 2992-2996.	0.6	104
118	Synergistic regulation of human cystathionine-Î²-synthase-1b promoter by transcription factors NF-YA isoforms and Sp1. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1579, 73-80.	2.4	29
119	Transcriptional regulation of the human cystathionine Î²-synthase âˆ'1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3. Biochemical Journal, 2001, 357, 97.	1.7	40
120	Transcriptional regulation of the human cystathionine Î²-synthase âˆ'1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3. Biochemical Journal, 2001, 357, 97-105.	1.7	64
121	Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine Î²-Synthase Gene by Differential Binding of Sp1/Sp3 to the âˆ'1b Promoter. Journal of Biological Chemistry, 2001, 276, 43570-43579.	1.6	36
122	Identification of mammalian-like purple acid phosphatases in a wide range of plants. Gene, 2000, 250, 117-125.	1.0	141
123	Coimmobilization of glucoamylase and glucose isomerase by molecular deposition technique for one-step conversion of dextrin to fructose. Journal of Biotechnology, 1999, 67, 33-40.	1.9	33
124	Binuclear Metal Centers in Plant Purple Acid Phosphatases: Feâ€"Mn in Sweet Potato and Feâ€"Zn in Soybean. Archives of Biochemistry and Biophysics, 1999, 370, 183-189.	1.4	161
125	Immobilization of glucose isomerase and its application in continuous production of high fructose syrup. Applied Biochemistry and Biotechnology, 1998, 69, 17-29.	1.4	6
126	Immobilization of glucose isomerase and its application in continuous production of high fructose syrup. Applied Biochemistry and Biotechnology, 1998, 69, 203-215.	1.4	11

#	Article	IF	Citations
127	Co-immobilization of cellulase and glucose isomerase by molecular deposition technique. Biotechnology Letters, 1997, 11, 359-361.	0.5	8
128	Co-immobilization of glucoamylase and glucose oxidase based on molecular deposition. Biotechnology Letters, 1996, 10, 861-866.	0.5	1